{"id":5843,"date":"2023-04-18T10:36:00","date_gmt":"2023-04-18T10:36:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5843"},"modified":"2025-01-15T03:04:02","modified_gmt":"2025-01-15T03:04:02","slug":"evidence-for-benefits-of-early-treatment-initiation-for-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/evidence-for-benefits-of-early-treatment-initiation-for-chronic-hepatitis-b\/","title":{"rendered":"Preuves des avantages de l&#039;initiation pr\u00e9coce du traitement de l&#039;h\u00e9patite B chronique"},"content":{"rendered":"<h2 class=\"wp-block-heading\" id=\"summary\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;h\u00e9patite B chronique (CHB) est la cause la plus fr\u00e9quente de carcinome h\u00e9patocellulaire (CHC) dans le monde. Le traitement antiviral r\u00e9duit le risque de CHC et de mortalit\u00e9 ; n\u00e9anmoins, dans le monde en 2019, seuls 2,21 TP3T des patients atteints d&#039;HCB ont re\u00e7u un traitement. Les directives internationales actuelles du CHB recommandent un traitement antiviral uniquement chez les sous-groupes de patients pr\u00e9sentant des signes \u00e9vidents de l\u00e9sions h\u00e9patiques. Cela contraste avec l&#039;h\u00e9patite C ou le VIH o\u00f9 un traitement pr\u00e9coce est recommand\u00e9 chez tous les patients infect\u00e9s, ind\u00e9pendamment des l\u00e9sions des organes cibles. Cette revue narrative vise \u00e0 fournir un aper\u00e7u des donn\u00e9es sur l&#039;initiation pr\u00e9coce du traitement antiviral et son impact \u00e9conomique potentiel connexe. Des recherches documentaires ont \u00e9t\u00e9 effectu\u00e9es \u00e0 l&#039;aide de PubMed et de r\u00e9sum\u00e9s de congr\u00e8s internationaux sur le foie (2019-2021). Les donn\u00e9es sur le risque de progression de la maladie et le CHC et l&#039;impact du traitement antiviral chez les patients actuellement in\u00e9ligibles ont \u00e9t\u00e9 r\u00e9sum\u00e9es. Des donn\u00e9es sur le rapport co\u00fbt-efficacit\u00e9 de l&#039;initiation pr\u00e9coce d&#039;un traitement antiviral ont \u00e9galement \u00e9t\u00e9 rassembl\u00e9es. L&#039;accumulation de donn\u00e9es mol\u00e9culaires, cliniques et \u00e9conomiques sugg\u00e8re que l&#039;initiation pr\u00e9coce d&#039;un traitement antiviral pourrait sauver de nombreuses vies gr\u00e2ce \u00e0 la pr\u00e9vention du CHC d&#039;une mani\u00e8re tr\u00e8s rentable. \u00c0 la lumi\u00e8re de ces donn\u00e9es, nous envisageons plusieurs strat\u00e9gies de traitement \u00e9largies alternatives qui pourraient favoriser une approche simplifi\u00e9e de \u00ab\u00a0traitement comme pr\u00e9vention\u00a0\u00bb.<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/cdafound.org\/wp-content\/uploads\/2023\/06\/Lim-2023-Evidence-for-early-treatmetn-of-HBV.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts [&hellip;]<\/p>\n","protected":false},"author":939,"featured_media":5844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[13,21,12],"publication-author":[110,97,107,113,108,111,114,112,109],"class_list":["post-5843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-global","tag-hbv","tag-modelling","publication-author-douglas-dieterich","publication-author-homie-razavi","publication-author-jia-horng-kao","publication-author-john-f-flaherty","publication-author-leland-j-yee","publication-author-lewis-r-roberts","publication-author-patrick-t-f-kennedy","publication-author-w-ray-kim","publication-author-young-suk-lim"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/939"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=5843"}],"version-history":[{"count":3,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5843\/revisions"}],"predecessor-version":[{"id":7515,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/5843\/revisions\/7515"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/5844"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=5843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=5843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=5843"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=5843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}